OncoMatch/Clinical Trials/NCT04135664
Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
Is NCT04135664 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies chemoradiation for esophageal cancer.
Treatment: chemoradiation — The ad-ESD trial is phase III randomized trial to compare adjuvant esophagectomy and chemoradiation for patients with clinical stage N0 and pathological stage T1b squamous cell carcinoma (after endoscopic submucosal dissection).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CN0, PT1B
Clinical N0 stage diagnosed by imaging examinations. Pathological T1b stage confirmed by endoscopic submucosal dissection.
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: intervention treatment before endoscopic submucosal resection
Prior intervention treatment before endoscopic submucosal resection.
Cannot have received: intervention (surgery, chemoradiation, et al.) for other primary tumor disease
Prior intervention (surgery, chemoradiation, et al.) for other primary tumor disease.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04135664 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage CN0 or PT1B is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages